4 -0.27 (-6.32%) | 02-07 19:56 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 16.04 | 1-year : | 23.54 |
Resists | First : | 13.73 | Second : | 20.15 |
Pivot price | 4.54 ![]() |
|||
Supports | First : | 3.33 | Second : | 2.77 |
MAs | MA(5) : | 4.24 ![]() |
MA(20) : | 5.33 ![]() |
MA(100) : | 10.14 ![]() |
MA(250) : | 23.62 ![]() |
|
MACD | MACD : | -1 ![]() |
Signal : | -1.1 ![]() |
%K %D | K(14,3) : | 21.1 ![]() |
D(3) : | 20.3 ![]() |
RSI | RSI(14): 36.2 ![]() |
|||
52-week | High : | 69.44 | Low : | 3.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ REVB ] has closed above bottom band by 38.0%. Bollinger Bands are 31.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 4.36 - 4.39 | 4.39 - 4.4 |
Low: | 3.95 - 3.98 | 3.98 - 4.01 |
Close: | 4.07 - 4.12 | 4.12 - 4.15 |
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Fri, 24 Jan 2025
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - Business Wire
Fri, 24 Jan 2025
Revelation Biosciences stock hits 52-week low at $0.28 - Investing.com
Fri, 24 Jan 2025
Revelation Bio Announces 1:16 Reverse Split, Advances CKD Drug Trial to Phase 1b - StockTitan
Mon, 13 Jan 2025
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025 - Business Wire
Mon, 13 Jan 2025
Revelation Biosciences Plans Move to Nevada, Eyes $200K Annual Tax Savings - StockTitan
Mon, 06 Jan 2025
Revelation Bio Secures Nasdaq Listing, Advances Kidney Disease Drug After FDA Green Light - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 1 (M) |
Shares Float | 4 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 11.3 (%) |
Shares Short | 46 (K) |
Shares Short P.Month | 3 (K) |
EPS | -280.49 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.62 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -51 % |
Return on Equity (ttm) | -270.1 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -16.32 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -17 (M) |
Levered Free Cash Flow | -6 (M) |
PE Ratio | -0.02 |
PEG Ratio | 0 |
Price to Book value | 6.62 |
Price to Sales | 0 |
Price to Cash Flow | -0.13 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |